Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.43 USD | +3.14% | -3.56% | -28.10% |
04-09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
04-03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 445
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics
100.0
%
| 108 | 100.0 % | 331 | 100.0 % | +204.74% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 108 | 100.0 % | 331 | 100.0 % | +204.74% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13/10/13 |
Ryan Watts
FOU | Founder | 48 | 13/10/13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/19 |
Dana Andersen
CTO | Chief Tech/Sci/R&D Officer | - | 06/08/18 |
Carole Ho
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/05/15 |
Steve Krognes
BRD | Director/Board Member | 56 | 30/09/15 |
Laura G. Hansen
IRC | Investor Relations Contact | - | - |
Katie Peng
PRN | Corporate Officer/Principal | - | 26/09/21 |
Erica Kratz
LAW | General Counsel | - | - |
Chris Walsh
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 31/03/15 |
Jay Flatley
BRD | Director/Board Member | 71 | 31/03/15 |
David Schenkein
BRD | Director/Board Member | 66 | 31/03/15 |
Founder | 64 | 13/10/13 | |
Jennifer Cook
BRD | Director/Board Member | 58 | 05/11/18 |
Peter Klein
BRD | Director/Board Member | 61 | 15/03/18 |
Erik Harris
BRD | Director/Board Member | 54 | 06/02/22 |
Steve Krognes
BRD | Director/Board Member | 56 | 30/09/15 |
Nancy Thornberry
BRD | Director/Board Member | 67 | 07/01/21 |
Ryan Watts
FOU | Founder | 48 | 13/10/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 142,539,529 | 122,839,616 ( 86.18 %) | 0 | 86.18 % |
Company contact information
Denali Therapeutics, Inc.
161 Oyster Point Boulevard
94080, San Francisco
+650 866 8548
http://www.denalitherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.10% | 2.2B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DNLI Stock
- Company Denali Therapeutics Inc.